Global Acne Vulgaris

Acne Vulgaris Comprehensive Study by Application (Hospitals, Clinics, Others), Therapy Type (Systemic Therapy, Harmonal Therapy, Topical Combination Therapy, Others), Type of Lesions (Non inflammatory, Inflammatory) Players and Region - Global Market Outlook to 2026

Acne Vulgaris Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Acne Vulgaris Market?

Acne is defined as the common chronic skin disease that affects pediatric as well as adult patients. The main cause of acne vulgaris is the overproduction of oils in the sebaceous follicles of the skin. Some of the major drugs commonly associated with acne Anabolic steroids, Cetuximab, Corticosteroids, Cyclosporine, Halogens, Hormonal contraceptives, Isoniazid, Lithium, Phenytoin, Vitamin B12, among others.

The market study is being classified, by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Allergan plc (Ireland), Bayer AG (Germany), Cipher Pharmaceuticals (Canada), Hygeia Laboratories (India), Johnson & Johnson (United States), Bausch Health Companies Inc. (Canada), Novan (United States) and Vyome Therapeutics Inc. (India) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Acne Vulgaris market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Acne Vulgaris market by Type, Application and Region.

On the basis of geography, the market of Acne Vulgaris has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Demand for acene vulgaris has increased due to the increasing number of skin problems. For instance, according to an article published by Children's Specialty Group, In the United States, Acnevulgaris is the most common skin problem, In addition, affecting more than 80% of the population in the United States. Therefore, rising number of skin problems will affect the growth of the market in the future.

Market Trend
  • Growing Adoption of Acne Cure Products and Rise in the Disposable Incomes of Middle-Class People

Restraints
  • Stringent Rules as well as Regulation

Opportunities
  • Growing Demand from Emerging Market such as China, India, Brazil, among others

Challenges
  • High Cost of Treatment regrading Acne Vulgaris





Key Target Audience
Ace Vulgaris Manufacturers, Regulatory Bodies, Component Suppliers, Distributors and Others

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Others
By Therapy Type
  • Systemic Therapy
  • Harmonal Therapy
  • Topical Combination Therapy
  • Others

By Type of Lesions
  • Non inflammatory
  • Inflammatory

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Demand for acene vulgaris has increased due to the increasing number of skin problems. For instance, according to an article published by Children's Specialty Group, In the United States, Acnevulgaris is the most common skin problem, In addition, affecting more than 80% of the population in the United States. Therefore, rising number of skin problems will affect the growth of the market in the future.
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Treatment regrading Acne Vulgaris
    • 3.4. Market Trends
      • 3.4.1. Growing Adoption of Acne Cure Products and Rise in the Disposable Incomes of Middle-Class People
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acne Vulgaris, by Application, Therapy Type, Type of Lesions and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Acne Vulgaris (Value)
      • 5.2.1. Global Acne Vulgaris by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Acne Vulgaris by: Therapy Type (Value)
        • 5.2.2.1. Systemic Therapy
        • 5.2.2.2. Harmonal Therapy
        • 5.2.2.3. Topical Combination Therapy
        • 5.2.2.4. Others
      • 5.2.3. Global Acne Vulgaris by: Type of Lesions (Value)
        • 5.2.3.1. Non inflammatory
        • 5.2.3.2. Inflammatory
      • 5.2.4. Global Acne Vulgaris Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Acne Vulgaris (Volume)
      • 5.3.1. Global Acne Vulgaris by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Acne Vulgaris by: Therapy Type (Volume)
        • 5.3.2.1. Systemic Therapy
        • 5.3.2.2. Harmonal Therapy
        • 5.3.2.3. Topical Combination Therapy
        • 5.3.2.4. Others
      • 5.3.3. Global Acne Vulgaris by: Type of Lesions (Volume)
        • 5.3.3.1. Non inflammatory
        • 5.3.3.2. Inflammatory
      • 5.3.4. Global Acne Vulgaris Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Acne Vulgaris (Price)
  • 6. Acne Vulgaris: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cipher Pharmaceuticals (Canada)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Hygeia Laboratories (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bausch Health Companies Inc. (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novan (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Vyome Therapeutics Inc. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Acne Vulgaris Sale, by Application, Therapy Type, Type of Lesions and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Acne Vulgaris (Value)
      • 7.2.1. Global Acne Vulgaris by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Acne Vulgaris by: Therapy Type (Value)
        • 7.2.2.1. Systemic Therapy
        • 7.2.2.2. Harmonal Therapy
        • 7.2.2.3. Topical Combination Therapy
        • 7.2.2.4. Others
      • 7.2.3. Global Acne Vulgaris by: Type of Lesions (Value)
        • 7.2.3.1. Non inflammatory
        • 7.2.3.2. Inflammatory
      • 7.2.4. Global Acne Vulgaris Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Acne Vulgaris (Volume)
      • 7.3.1. Global Acne Vulgaris by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Acne Vulgaris by: Therapy Type (Volume)
        • 7.3.2.1. Systemic Therapy
        • 7.3.2.2. Harmonal Therapy
        • 7.3.2.3. Topical Combination Therapy
        • 7.3.2.4. Others
      • 7.3.3. Global Acne Vulgaris by: Type of Lesions (Volume)
        • 7.3.3.1. Non inflammatory
        • 7.3.3.2. Inflammatory
      • 7.3.4. Global Acne Vulgaris Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Acne Vulgaris (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acne Vulgaris: by Application(USD Million)
  • Table 2. Acne Vulgaris Hospitals , by Region USD Million (2015-2020)
  • Table 3. Acne Vulgaris Clinics , by Region USD Million (2015-2020)
  • Table 4. Acne Vulgaris Others , by Region USD Million (2015-2020)
  • Table 5. Acne Vulgaris: by Therapy Type(USD Million)
  • Table 6. Acne Vulgaris Systemic Therapy , by Region USD Million (2015-2020)
  • Table 7. Acne Vulgaris Harmonal Therapy , by Region USD Million (2015-2020)
  • Table 8. Acne Vulgaris Topical Combination Therapy , by Region USD Million (2015-2020)
  • Table 9. Acne Vulgaris Others , by Region USD Million (2015-2020)
  • Table 10. Acne Vulgaris: by Type of Lesions(USD Million)
  • Table 11. Acne Vulgaris Non inflammatory , by Region USD Million (2015-2020)
  • Table 12. Acne Vulgaris Inflammatory , by Region USD Million (2015-2020)
  • Table 13. South America Acne Vulgaris, by Country USD Million (2015-2020)
  • Table 14. South America Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 15. South America Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 16. South America Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 17. Brazil Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 18. Brazil Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 19. Brazil Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 20. Argentina Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 21. Argentina Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 22. Argentina Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 23. Rest of South America Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 24. Rest of South America Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 25. Rest of South America Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 26. Asia Pacific Acne Vulgaris, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 28. Asia Pacific Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 29. Asia Pacific Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 30. China Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 31. China Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 32. China Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 33. Japan Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 34. Japan Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 35. Japan Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 36. India Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 37. India Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 38. India Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 39. South Korea Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 40. South Korea Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 41. South Korea Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 42. Taiwan Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 43. Taiwan Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 44. Taiwan Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 45. Australia Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 46. Australia Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 47. Australia Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 51. Europe Acne Vulgaris, by Country USD Million (2015-2020)
  • Table 52. Europe Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 53. Europe Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 54. Europe Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 55. Germany Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 56. Germany Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 57. Germany Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 58. France Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 59. France Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 60. France Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 61. Italy Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 62. Italy Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 63. Italy Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 64. United Kingdom Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 65. United Kingdom Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 66. United Kingdom Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 67. Netherlands Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 68. Netherlands Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 69. Netherlands Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 70. Rest of Europe Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 71. Rest of Europe Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 72. Rest of Europe Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 73. MEA Acne Vulgaris, by Country USD Million (2015-2020)
  • Table 74. MEA Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 75. MEA Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 76. MEA Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 77. Middle East Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 78. Middle East Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 79. Middle East Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 80. Africa Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 81. Africa Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 82. Africa Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 83. North America Acne Vulgaris, by Country USD Million (2015-2020)
  • Table 84. North America Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 85. North America Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 86. North America Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 87. United States Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 88. United States Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 89. United States Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 90. Canada Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 91. Canada Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 92. Canada Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 93. Mexico Acne Vulgaris, by Application USD Million (2015-2020)
  • Table 94. Mexico Acne Vulgaris, by Therapy Type USD Million (2015-2020)
  • Table 95. Mexico Acne Vulgaris, by Type of Lesions USD Million (2015-2020)
  • Table 96. Acne Vulgaris Sales: by Application(M Units)
  • Table 97. Acne Vulgaris Sales Hospitals , by Region M Units (2015-2020)
  • Table 98. Acne Vulgaris Sales Clinics , by Region M Units (2015-2020)
  • Table 99. Acne Vulgaris Sales Others , by Region M Units (2015-2020)
  • Table 100. Acne Vulgaris Sales: by Therapy Type(M Units)
  • Table 101. Acne Vulgaris Sales Systemic Therapy , by Region M Units (2015-2020)
  • Table 102. Acne Vulgaris Sales Harmonal Therapy , by Region M Units (2015-2020)
  • Table 103. Acne Vulgaris Sales Topical Combination Therapy , by Region M Units (2015-2020)
  • Table 104. Acne Vulgaris Sales Others , by Region M Units (2015-2020)
  • Table 105. Acne Vulgaris Sales: by Type of Lesions(M Units)
  • Table 106. Acne Vulgaris Sales Non inflammatory , by Region M Units (2015-2020)
  • Table 107. Acne Vulgaris Sales Inflammatory , by Region M Units (2015-2020)
  • Table 108. South America Acne Vulgaris Sales, by Country M Units (2015-2020)
  • Table 109. South America Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 110. South America Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 111. South America Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 112. Brazil Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 113. Brazil Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 114. Brazil Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 115. Argentina Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 116. Argentina Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 117. Argentina Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 118. Rest of South America Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 119. Rest of South America Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 120. Rest of South America Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 121. Asia Pacific Acne Vulgaris Sales, by Country M Units (2015-2020)
  • Table 122. Asia Pacific Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 123. Asia Pacific Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 124. Asia Pacific Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 125. China Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 126. China Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 127. China Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 128. Japan Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 129. Japan Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 130. Japan Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 131. India Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 132. India Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 133. India Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 134. South Korea Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 135. South Korea Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 136. South Korea Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 137. Taiwan Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 138. Taiwan Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 139. Taiwan Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 140. Australia Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 141. Australia Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 142. Australia Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 143. Rest of Asia-Pacific Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 144. Rest of Asia-Pacific Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 146. Europe Acne Vulgaris Sales, by Country M Units (2015-2020)
  • Table 147. Europe Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 148. Europe Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 149. Europe Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 150. Germany Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 151. Germany Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 152. Germany Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 153. France Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 154. France Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 155. France Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 156. Italy Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 157. Italy Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 158. Italy Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 159. United Kingdom Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 160. United Kingdom Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 161. United Kingdom Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 162. Netherlands Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 163. Netherlands Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 164. Netherlands Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 165. Rest of Europe Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 166. Rest of Europe Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 167. Rest of Europe Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 168. MEA Acne Vulgaris Sales, by Country M Units (2015-2020)
  • Table 169. MEA Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 170. MEA Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 171. MEA Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 172. Middle East Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 173. Middle East Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 174. Middle East Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 175. Africa Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 176. Africa Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 177. Africa Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 178. North America Acne Vulgaris Sales, by Country M Units (2015-2020)
  • Table 179. North America Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 180. North America Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 181. North America Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 182. United States Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 183. United States Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 184. United States Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 185. Canada Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 186. Canada Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 187. Canada Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 188. Mexico Acne Vulgaris Sales, by Application M Units (2015-2020)
  • Table 189. Mexico Acne Vulgaris Sales, by Therapy Type M Units (2015-2020)
  • Table 190. Mexico Acne Vulgaris Sales, by Type of Lesions M Units (2015-2020)
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Acne Vulgaris: by Application(USD Million)
  • Table 200. Acne Vulgaris Hospitals , by Region USD Million (2021-2026)
  • Table 201. Acne Vulgaris Clinics , by Region USD Million (2021-2026)
  • Table 202. Acne Vulgaris Others , by Region USD Million (2021-2026)
  • Table 203. Acne Vulgaris: by Therapy Type(USD Million)
  • Table 204. Acne Vulgaris Systemic Therapy , by Region USD Million (2021-2026)
  • Table 205. Acne Vulgaris Harmonal Therapy , by Region USD Million (2021-2026)
  • Table 206. Acne Vulgaris Topical Combination Therapy , by Region USD Million (2021-2026)
  • Table 207. Acne Vulgaris Others , by Region USD Million (2021-2026)
  • Table 208. Acne Vulgaris: by Type of Lesions(USD Million)
  • Table 209. Acne Vulgaris Non inflammatory , by Region USD Million (2021-2026)
  • Table 210. Acne Vulgaris Inflammatory , by Region USD Million (2021-2026)
  • Table 211. South America Acne Vulgaris, by Country USD Million (2021-2026)
  • Table 212. South America Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 213. South America Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 214. South America Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 215. Brazil Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 216. Brazil Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 217. Brazil Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 218. Argentina Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 219. Argentina Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 220. Argentina Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 221. Rest of South America Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 222. Rest of South America Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 223. Rest of South America Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 224. Asia Pacific Acne Vulgaris, by Country USD Million (2021-2026)
  • Table 225. Asia Pacific Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 226. Asia Pacific Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 227. Asia Pacific Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 228. China Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 229. China Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 230. China Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 231. Japan Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 232. Japan Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 233. Japan Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 234. India Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 235. India Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 236. India Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 237. South Korea Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 238. South Korea Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 239. South Korea Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 240. Taiwan Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 241. Taiwan Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 242. Taiwan Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 243. Australia Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 244. Australia Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 245. Australia Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 247. Rest of Asia-Pacific Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 248. Rest of Asia-Pacific Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 249. Europe Acne Vulgaris, by Country USD Million (2021-2026)
  • Table 250. Europe Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 251. Europe Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 252. Europe Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 253. Germany Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 254. Germany Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 255. Germany Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 256. France Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 257. France Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 258. France Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 259. Italy Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 260. Italy Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 261. Italy Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 262. United Kingdom Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 263. United Kingdom Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 264. United Kingdom Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 265. Netherlands Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 266. Netherlands Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 267. Netherlands Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 268. Rest of Europe Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 269. Rest of Europe Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 270. Rest of Europe Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 271. MEA Acne Vulgaris, by Country USD Million (2021-2026)
  • Table 272. MEA Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 273. MEA Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 274. MEA Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 275. Middle East Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 276. Middle East Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 277. Middle East Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 278. Africa Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 279. Africa Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 280. Africa Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 281. North America Acne Vulgaris, by Country USD Million (2021-2026)
  • Table 282. North America Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 283. North America Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 284. North America Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 285. United States Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 286. United States Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 287. United States Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 288. Canada Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 289. Canada Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 290. Canada Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 291. Mexico Acne Vulgaris, by Application USD Million (2021-2026)
  • Table 292. Mexico Acne Vulgaris, by Therapy Type USD Million (2021-2026)
  • Table 293. Mexico Acne Vulgaris, by Type of Lesions USD Million (2021-2026)
  • Table 294. Acne Vulgaris Sales: by Application(M Units)
  • Table 295. Acne Vulgaris Sales Hospitals , by Region M Units (2021-2026)
  • Table 296. Acne Vulgaris Sales Clinics , by Region M Units (2021-2026)
  • Table 297. Acne Vulgaris Sales Others , by Region M Units (2021-2026)
  • Table 298. Acne Vulgaris Sales: by Therapy Type(M Units)
  • Table 299. Acne Vulgaris Sales Systemic Therapy , by Region M Units (2021-2026)
  • Table 300. Acne Vulgaris Sales Harmonal Therapy , by Region M Units (2021-2026)
  • Table 301. Acne Vulgaris Sales Topical Combination Therapy , by Region M Units (2021-2026)
  • Table 302. Acne Vulgaris Sales Others , by Region M Units (2021-2026)
  • Table 303. Acne Vulgaris Sales: by Type of Lesions(M Units)
  • Table 304. Acne Vulgaris Sales Non inflammatory , by Region M Units (2021-2026)
  • Table 305. Acne Vulgaris Sales Inflammatory , by Region M Units (2021-2026)
  • Table 306. South America Acne Vulgaris Sales, by Country M Units (2021-2026)
  • Table 307. South America Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 308. South America Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 309. South America Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 310. Brazil Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 311. Brazil Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 312. Brazil Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 313. Argentina Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 314. Argentina Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 315. Argentina Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 316. Rest of South America Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 317. Rest of South America Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 318. Rest of South America Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 319. Asia Pacific Acne Vulgaris Sales, by Country M Units (2021-2026)
  • Table 320. Asia Pacific Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 321. Asia Pacific Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 322. Asia Pacific Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 323. China Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 324. China Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 325. China Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 326. Japan Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 327. Japan Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 328. Japan Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 329. India Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 330. India Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 331. India Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 332. South Korea Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 333. South Korea Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 334. South Korea Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 335. Taiwan Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 336. Taiwan Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 337. Taiwan Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 338. Australia Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 339. Australia Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 340. Australia Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 341. Rest of Asia-Pacific Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 342. Rest of Asia-Pacific Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 343. Rest of Asia-Pacific Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 344. Europe Acne Vulgaris Sales, by Country M Units (2021-2026)
  • Table 345. Europe Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 346. Europe Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 347. Europe Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 348. Germany Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 349. Germany Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 350. Germany Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 351. France Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 352. France Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 353. France Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 354. Italy Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 355. Italy Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 356. Italy Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 357. United Kingdom Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 358. United Kingdom Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 359. United Kingdom Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 360. Netherlands Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 361. Netherlands Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 362. Netherlands Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 363. Rest of Europe Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 364. Rest of Europe Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 365. Rest of Europe Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 366. MEA Acne Vulgaris Sales, by Country M Units (2021-2026)
  • Table 367. MEA Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 368. MEA Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 369. MEA Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 370. Middle East Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 371. Middle East Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 372. Middle East Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 373. Africa Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 374. Africa Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 375. Africa Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 376. North America Acne Vulgaris Sales, by Country M Units (2021-2026)
  • Table 377. North America Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 378. North America Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 379. North America Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 380. United States Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 381. United States Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 382. United States Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 383. Canada Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 384. Canada Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 385. Canada Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 386. Mexico Acne Vulgaris Sales, by Application M Units (2021-2026)
  • Table 387. Mexico Acne Vulgaris Sales, by Therapy Type M Units (2021-2026)
  • Table 388. Mexico Acne Vulgaris Sales, by Type of Lesions M Units (2021-2026)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acne Vulgaris: by Application USD Million (2015-2020)
  • Figure 5. Global Acne Vulgaris: by Therapy Type USD Million (2015-2020)
  • Figure 6. Global Acne Vulgaris: by Type of Lesions USD Million (2015-2020)
  • Figure 7. South America Acne Vulgaris Share (%), by Country
  • Figure 8. Asia Pacific Acne Vulgaris Share (%), by Country
  • Figure 9. Europe Acne Vulgaris Share (%), by Country
  • Figure 10. MEA Acne Vulgaris Share (%), by Country
  • Figure 11. North America Acne Vulgaris Share (%), by Country
  • Figure 12. Global Acne Vulgaris: by Application M Units (2015-2020)
  • Figure 13. Global Acne Vulgaris: by Therapy Type M Units (2015-2020)
  • Figure 14. Global Acne Vulgaris: by Type of Lesions M Units (2015-2020)
  • Figure 15. South America Acne Vulgaris Share (%), by Country
  • Figure 16. Asia Pacific Acne Vulgaris Share (%), by Country
  • Figure 17. Europe Acne Vulgaris Share (%), by Country
  • Figure 18. MEA Acne Vulgaris Share (%), by Country
  • Figure 19. North America Acne Vulgaris Share (%), by Country
  • Figure 20. Global Acne Vulgaris share by Players 2020 (%)
  • Figure 21. Global Acne Vulgaris share by Players (Top 3) 2020(%)
  • Figure 22. Global Acne Vulgaris share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 28. Cipher Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Cipher Pharmaceuticals (Canada) Revenue: by Geography 2020
  • Figure 30. Hygeia Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 31. Hygeia Laboratories (India) Revenue: by Geography 2020
  • Figure 32. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 34. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2020
  • Figure 36. Novan (United States) Revenue, Net Income and Gross profit
  • Figure 37. Novan (United States) Revenue: by Geography 2020
  • Figure 38. Vyome Therapeutics Inc. (India) Revenue, Net Income and Gross profit
  • Figure 39. Vyome Therapeutics Inc. (India) Revenue: by Geography 2020
  • Figure 40. Global Acne Vulgaris: by Application USD Million (2021-2026)
  • Figure 41. Global Acne Vulgaris: by Therapy Type USD Million (2021-2026)
  • Figure 42. Global Acne Vulgaris: by Type of Lesions USD Million (2021-2026)
  • Figure 43. South America Acne Vulgaris Share (%), by Country
  • Figure 44. Asia Pacific Acne Vulgaris Share (%), by Country
  • Figure 45. Europe Acne Vulgaris Share (%), by Country
  • Figure 46. MEA Acne Vulgaris Share (%), by Country
  • Figure 47. North America Acne Vulgaris Share (%), by Country
  • Figure 48. Global Acne Vulgaris: by Application M Units (2021-2026)
  • Figure 49. Global Acne Vulgaris: by Therapy Type M Units (2021-2026)
  • Figure 50. Global Acne Vulgaris: by Type of Lesions M Units (2021-2026)
  • Figure 51. South America Acne Vulgaris Share (%), by Country
  • Figure 52. Asia Pacific Acne Vulgaris Share (%), by Country
  • Figure 53. Europe Acne Vulgaris Share (%), by Country
  • Figure 54. MEA Acne Vulgaris Share (%), by Country
  • Figure 55. North America Acne Vulgaris Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan plc (Ireland)
  • Bayer AG (Germany)
  • Cipher Pharmaceuticals (Canada)
  • Hygeia Laboratories (India)
  • Johnson & Johnson (United States)
  • Bausch Health Companies Inc. (Canada)
  • Novan (United States)
  • Vyome Therapeutics Inc. (India)
Select User Access Type

Key Highlights of Report


Sep 2021 244 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acne Vulgaris Quantitative research analysis
Global Acne Vulgaris Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Demand for acene vulgaris has increased due to the increasing number of skin problems. For instance, according to an article published by Children's Specialty Group, In the United States, Acnevulgaris is the most common skin problem, In addition, affecting more than 80% of the population in the United States. Therefore, rising number of skin problems will affect the growth of the market in the future." is seen as one of major growth factors of Acne Vulgaris Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Acne Vulgaris Market in coming years.

Know More About Global Acne Vulgaris Report?

Have a Query? Click Here

Other Related Reports

Myasthenia Gravis Comprehensive Study by Type (Congenital Hereditary, Autoimmune Disease), Application (Hospital, Medical Clinical Research Center, Others), Treatment type (Therapeutic approach, Medi...
$ 3750
Transdermal Skin Patches Comprehensive Study by Type (Drug in Adhesive, Matrix, Reservoir, Vapor, Other), Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Use (Hospital Ph...
$ 3450
Kidney Cancer Drugs Comprehensive Study by Type (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus)...
$ 3650
Obesity Treatment Comprehensive Study by Application (Children, Adults), Drugs (Combination Drugs, Appetite Suppressants, Malabsorption, Satiety), Treatment (Medication, Surgery, Lifestyle Changes), ...
$ 3750
Plant Sterol Esters Comprehensive Study by Type (Oil, Powder), End Users (Food & Beverages, Dairy Products, Pharmaceutical, Cosmetics) Players and Region - Global Market Outlook to 2026
$ 3500
Companion Diagnostics Comprehensive Study by End-users (Pharma Companies, Reference Laboratories, CRO, Others), Product & Service (Assay kits & Reagents, Software & Services), Technology Type (Polyme...
$ 3750